Literature DB >> 11003996

Impact of gender and endothelin on renal vasodilation and hyperfiltration induced by relaxin in conscious rats.

L A Danielson1, L J Kercher, K P Conrad.   

Abstract

Chronic administration of the hormone relaxin elicits renal vasodilation that is dependent on nitric oxide (NO) in both conscious intact and ovariectomized female rats. Our first objective was to test whether the hormone, when administered to approximate serum concentrations found in midterm pregnant rats, induces renal vasodilation in males. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) increased significantly, on average, by 33 and 49% over baseline, respectively, after 5 days of recombinant human relaxin (rhRLX) administration to 12 conscious male rats by subcutaneous osmotic minipump. There were also significant decreases in hematocrit, plasma osmolality, and sodium concentration. Another objective was to determine whether endogenous endothelin (ET; via the endothelial ET(B) receptor) mediates the NO-dependent renal vasodilation produced by relaxin. rhRLX or vehicle was administered to conscious female rats (n = 9 and 8 rats, respectively). On the fifth day, baseline GFR and ERPF were both increased, on average, by 20-30% in the rats administered rhRLX (P < 0.05 vs. vehicle). Next, the specific ET(B)-receptor antagonist RES-701-1 was infused intravenously over 4 h in both groups of rats. In response to RES-701-1, there was a significant decline in both GFR and ERPF in the rats receiving rhRLX such that renal function converged in the two groups of animals. We conclude 1) relaxin induces marked changes in the renal circulation and in osmoregulation regardless of gender and 2) relaxin-induced renal vasodilation and hyperfiltration are mediated by endothelin through the endothelial ET(B) receptor subtype and NO.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11003996     DOI: 10.1152/ajpregu.2000.279.4.R1298

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  30 in total

1.  Relaxin is essential for renal vasodilation during pregnancy in conscious rats.

Authors:  J Novak; L A Danielson; L J Kerchner; O D Sherwood; R J Ramirez; P A Moalli; K P Conrad
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 2.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

3.  Impact of endothelin A receptor antagonist selectivity in chronic nitric oxide synthase inhibition-induced fetal growth restriction in the rat.

Authors:  Mark G Neerhof; Sylvia Synowiec; Saira Khan; Larry G Thaete
Journal:  Hypertens Pregnancy       Date:  2010       Impact factor: 2.108

Review 4.  Animal models of preeclampsia.

Authors:  Eduardo Podjarny; Gyorgy Losonczy; Chris Baylis
Journal:  Semin Nephrol       Date:  2004-11       Impact factor: 5.299

5.  Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.

Authors:  Jennifer M Sasser; Miklos Molnar; Chris Baylis
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

Review 6.  Maternal vasodilation in pregnancy: the emerging role of relaxin.

Authors:  Kirk P Conrad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-25       Impact factor: 3.619

Review 7.  Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.

Authors:  Roland E Schmieder; Veselin Mitrovic; Christian Hengstenberg
Journal:  Clin Res Cardiol       Date:  2015-03-19       Impact factor: 5.460

Review 8.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 9.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

Authors:  Sam L Teichman; Elaine Unemori; Thomas Dschietzig; Kirk Conrad; Adriaan A Voors; John R Teerlink; G Michael Felker; Marco Metra; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

10.  Receptor-induced dilatation in the systemic and intrarenal adaptation to pregnancy in rats.

Authors:  Vanessa M Ferreira; Thiago S Gomes; Luciana A Reis; Alice T Ferreira; Clara V Razvickas; Nestor Schor; Mirian A Boim
Journal:  PLoS One       Date:  2009-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.